Northleaf Completes Investment in CCM Hockey alongside Altor Equity Partners
Northleaf Capital Partners (“Northleaf”), a global private markets investment firm, today announced that funds under its management have completed an investment in CCM Hockey (“CCM” or “the Company”). Northleaf partnered with Altor Equity Partners (“Altor”), a leading European middle-market private equity firm, to acquire the business. Financial terms of the transaction were not disclosed.
Founded in 1899, CCM is a leading designer, manufacturer, and distributor of hockey equipment, including sticks, skates, protective gear, helmets, goalie equipment, and apparel. Headquartered in Montreal, Canada, the Company operates in more than 40 countries and is represented by many NHL and PWHL superstars.
“Northleaf is proud to be a part of Canadian hockey history and support CCM’s next stage of growth, alongside a trusted mid-market sponsor like Altor,” said Michael Flood, Head of Private Equity at Northleaf. “CCM’s iconic brand and strong industry tailwinds, coupled with Altor’s deep consumer experience, create a very attractive opportunity to generate strong risk-adjusted returns for our investors.”
“Northleaf is an experienced investor with a global network and deep knowledge in the local Canadian market and we’re excited to be partnering with their team,” said Andreas Källström Säfweräng, Partner and Head of the Consumer Sector at Altor. “Together, our resources and expertise will allow CCM to accelerate its strategic initiatives and unlock new growth opportunities.”
“This is an exciting new chapter to mark CCM’s 125-year anniversary,” said Marrouane Nabih, CEO at CCM Hockey. “Northleaf and Altor’s partnership will enable us to scale our ambitious growth strategy and pursue new opportunities across CCM’s global portfolio. Our collective commitment to grow the game of hockey and our passion for product innovation and engagement to providing high-performance and quality products to our consumers makes this a compelling partnership.”
For over 20 years, Northleaf has built a reputation as an established global private markets investor and trusted partner to mid-market companies and private equity sponsors. With a proven track record, strong underwriting capabilities, and a deep understanding of private equity investing, including co-investments, secondaries, structured capital, and primary investments, Northleaf is recognized as a partner of choice. Northleaf has completed more than 150 private equity co-investments, and our investment in CCM further demonstrates the firm’s ability to invest alongside leading private equity sponsors in high-quality mid-market companies.
About Northleaf Capital Partners
Northleaf Capital Partners is a global private markets investment firm with more than US$27 billion in private equity, private credit and infrastructure commitments raised to date from public, corporate and multi-employer pension plans, endowments, foundations, financial institutions and family offices. Northleaf’s 275-person team is located in Toronto, Chicago, London, Los Angeles, Melbourne, Menlo Park, Montreal, New York, Seoul, and Tokyo. Northleaf sources, evaluates and manages private markets investments, with a focus on mid-market companies and assets. For more information on Northleaf, please visit www.northleafcapital.com.
About Altor
Since inception, the family of Altor funds has raised more than EUR 11 billion in total commitments. The funds have invested in just south of 100 companies. The investments have been made in medium-sized predominantly Nordic and DACH companies with the aim to create value through growth initiatives and operational improvements. Among current and past investments are Marshall, Rossignol, Toteme, Helly Hansen, and Revolutionrace.
About CCM
CCM Hockey, a leading designer, manufacturer, and marketer of hockey equipment, and Jackson Ultima, a global leader in figure skate boots, blades and complete skates. With its headquarters located in Montreal, the company has operations in Canada, the United States, Europe and Asia. CCM Hockey equips more professional hockey players than any other company, including NHL and PWHL stars like Auston Matthews, Sidney Crosby, Connor McDavid, Kendall Coyne-Schofield, and Sarah Nurse. CCM Hockey is also an official supplier of the PWHL, and the official outfitter of the American Hockey League, and several NCAA and National teams.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106264161/en/
Contacts
Media Contacts:
Sneha Satish
Stanton
t: +1.646.502.3556
e: ssatish@stantonprm.com
Gina Lee
Northleaf
Director, Corporate Communications & Corporate Investor Relations
t: +1.416.389.7667
e: gina.lee@northleafcapital.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom